CALIWAY BIOPHARMACEUTICALS CO., LTD.

Andere talen Caliway Biopharmaceuticals Co., Ltd.

Aandelen

6919

TW0006919004

slotkoers Taipei Exchange Andere beurzen 00:00:00 31-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
416,5 ^TWD	-0,95%		+0,85%	+117,78%

13/05	Caliway Biopharmaceuticals Co, Ltd. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
25/04	Caliway Biopharmaceuticals Co, Ltd. Kondigt aan dat CBL-514 Fase 2 Studie voor Cellulitisbehandeling aan alle primaire en secundaire eindpunten voldeed	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints	25/04
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease	15/02
Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction	23/01
Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease	08/01
Caliway's CBL-514 Achieves Better Efficacy Than Liposuction, Reducing over 300Ml of Subcutaneous Fat on Average in CBL-0202 Study	02-10-23
Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7	13-09-23
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	11-08-23
Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite	28-06-23
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	31-05-23
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	31-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Beurs
Aandelen
Koers 6919
Nieuws Caliway Biopharmaceuticals Co., Ltd.
Andere talen

-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.

PROFITEER NU